Business Wire

BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE INNOVATIVE ANTIBODIES FROM A*STAR FOR TARGETED CANCER THERAPIES

2.6.2022 16:10:00 EEST | Business Wire | Press release

Share

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR. Boehringer Ingelheim aims to use these antibodies to direct therapeutic effector mechanisms such as antibody-drug conjugates (ADCs) and T-cell engagers exclusively to tumor cells, and to that end develop a range of highly targeted cancer treatments.

“Boehringer Ingelheim believes that these promising antibodies in-licensed from A*STAR will help us advance potent therapeutic candidates against key molecular cancer targets,” says Clive R. Wood, Senior Corporate Vice President and Global Head of Discovery Research at Boehringer Ingelheim and continues: “We look forward to developing these assets for a broad range of cancers with the goal to deliver breakthrough opportunities for patients.”

Boehringer Ingelheim is pioneering a range of versatile therapeutic platforms in order to develop innovative medicines that target the tumor directly (tumor cell-directed therapies) or that enable the immune system to target the tumor (immune cell-targeted therapies). One tumor cell-directed modality is antibody drug conjugates, which allows for delivery of toxins directly into tumor cells. Another is T-cell engagers facilitating direct contact between T-cells and tumor cells, leading to T-cell-mediated killing of the tumor. Both technologies are directed towards markers on the surface of cancer cells, also known as antigens, in order to attack tumor cells but spare healthy tissues.

The innovative antibodies from A*STAR can potentially enable the development of safer, more efficacious therapies as they selectively bind to antigens that are highly expressed on tumor cells but are absent on normal healthy tissues.

Under the terms of the agreement, Boehringer Ingelheim will be responsible for further research, preclinical and clinical development as well as commercialization of targeted cancer therapies using the antibodies from A*STAR. A*STAR may receive payments totalling >100 million EUR in upfront and success-based development and commercialization milestones.

The technology used to identify the unique A*STAR antibodies resulted from a multi-institutional collaboration in Singapore. A*STAR’s Genome Institute of Singapore (GIS) and Institute of Bioengineering & Bioimaging (IBB) generated antibodies which exclusively target antigens that were initially identified from gastric cancer cells. Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development hosted by A*STAR, then optimized the antibodies and confirmed their applicability to a range of other solid cancers. EDDC also demonstrated the utility of these antibodies in directing different therapeutic modalities selectively to cancer cells.

Professor Damian O'Connell, Chief Executive Officer of EDDC, says, “As Singapore's national drug discovery and development platform, EDDC is proud to translate great science in Singapore into valuable assets that can enable the precise treatment of cancer. We believe that Boehringer Ingelheim, with its broad expertise and technologies, is the right partner to maximize the potential of these antibodies for the development of safer, more targeted therapies for cancer patients.”

Professor Tan Sze Wee, Assistant Chief Executive (Enterprise) of A*STAR, says, “These antibodies were developed in Singapore through close collaboration across multiple institutions. There was also strong support by the Singapore Gastric Cancer Consortium. The agreement is testament to the best-in-class research taking place in Singapore. Cancer is a devastating disease, and we hope the fruits of our research can improve patient outcomes.”

Please click on the link for “Note to Editors’ and ‘References’:

https://www.boehringer-ingelheim.com/partnering/human-health-partnering/license-deal-astar-develop-cancer-antibodies

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media queries and clarifications:

Dr. Reinhard Malin
Innovation Unit Communications
Corporate Affairs
Boehringer Ingelheim
Tel: +49 6132 77-90815
Email: reinhard.malin@boehringeringelheim.com

Owen Sia
Assistant Head, Corporate Communications
Agency for Science, Technology and Research
Tel: +65 6517 7866
Email: owen_sia@hq.a-star.edu.sg

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Every Entrepreneur Needs Someone to Call: Lenovo and Eva Longoria Open a New Line of Support for Entrepreneurs with “Call Eva”8.9.2026 13:00:00 EEST | Press release

Lenovo today announced Call Eva, a new initiative from Lenovo’s global Backing Every Business program that gives entrepreneurs a direct line to call Eva Longoria, Lenovo’s global ambassador, for insights on business growth, leadership and entrepreneurship. Entrepreneurs can now call and leave a voice note with their biggest business questions. Select callers may then be contacted and offered the opportunity to speak with Eva, live on September 16. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908095710/en/ Running a business can feel lonely. The decisions are constant, the challenges are personal and, too often, entrepreneurs are left asking the same question: Who can I call who actually understands what I’m going through? The concept of Call Eva is simple: every entrepreneur needs someone they can call. As a business owner herself, Longoria understands what it means to build, lead and take risks. Beyond her work as an a

57% of Brands Can't Prove ROI on Sports Fan Engagement Despite Rising Investment8.9.2026 12:30:00 EEST | Press release

Research commissioned by Infobip, the global AI-first cloud communications platform celebrating 20 years, shows brands are significantly increasing investment in sports fan engagement even as many struggle to prove business impact. The global study of 500 marketing and digital leaders across industries, including retail, financial services, telecoms, travel, and food & beverage in 11 markets found that brands currently allocate an average of 13% of annual marketing budgets to sports-related activations, and nearly 73% expect investment to increase over the next 12 months. Yet while live sports moments generate the highest levels of fan engagement, nearly half (47%) of organizations admit they struggle to deliver real-time engagement during live events, and more than half (57%) say it is difficult to prove the ROI of their sports marketing investments. Ben Lewis, VP Marketing and Growth at Infobip, said: “Half of brands can't prove the ROI of their sports marketing – that's not a measur

Red Sea Global Unveils Nammos Resort AMAALA, Introducing Nammos’ First Resort Hotel Globally8.9.2026 11:59:00 EEST | Press release

Red Sea Global (RSG), the regenerative tourism developer, today announced the opening of Nammos Resort AMAALA, marking the launch of Nammos’ first resort hotel globally and a significant addition to AMAALA’s growing lifestyle and hospitality offering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908621917/en/ A marvellous view of the night sky from inside the resort hotel Set along the shores of Triple Bay with sweeping views across the Red Sea and Dumega Bay and designed around Nammos’ philosophy of Endless Joy, Nammos Resort AMAALA introduces the brand’s distinctive blend of Mediterranean sophistication and vibrant social energy to one of the world’s most comprehensive wellness destinations. “Nammos Resort AMAALA strengthens the diversity of experiences available across the destination bringing the unmistakable energy and spirit of Mykonos to the Saudi Red Sea coast. As AMAALA continues to expand with each new opening

Icon Solutions and MongoDB Benchmark Shows IPF Processing 6,000 Payments per Second with Zero Data Loss Under Failure8.9.2026 11:54:00 EEST | Press release

Icon Solutions and MongoDB today published the results of a joint benchmark showing that the Icon Payments Framework (IPF), running on MongoDB Atlas, processed 6,000 end-to-end payment transactions per second (around 430,000 database operations per second) with a mean end-to-end latency of 0.51 seconds, and recovered from both application and database node failures with zero data loss. Account-to-account payment volumes are moving rapidly onto instant rails. Traffic is migrating from net-settlement schemes to instant schemes, and direct debit volumes are expected to partially move to request-to-pay with settlement through instant schemes. For banks, that means sharper traffic peaks, a growing share of payments bound to scheme SLAs of a few seconds, and no tolerance for downtime. Sustaining several thousand payments per second while maintaining resilience, availability and low latency is routinely underestimated by institutions that self-build, and retro-fitting legacy platforms for alw

NTT DATA Deploys AI-Powered Platform to Elevate Global Infrastructure Operations8.9.2026 11:00:00 EEST | Press release

NTT DATA, a global leader in AI, digital business and technology services, is expanding the deployment of its AI-powered infrastructure operations platform to support complex global enterprise environments. The platform combines real time monitoring, predictive analytics and intelligent automation to enhance operational resilience, efficiency and visibility. Deployment of these capabilities includes support for one of the largest commercial vehicle manufacturers. “Our AI-powered platform significantly increases transparency and automation, providing the foundation for greater stability, faster response times and a future-ready IT architecture,” said Abhijit Dubey, CEO and Chief AI Officer, NTT DATA, Inc. “Our work with Daimler Truck is one example of how we canoperate global IT infrastructures securely, responsibly and at scale with clear business outcomes.” NTT DATA provides clients with an integrated, AI-powered platform to enable intelligent, data-driven operations. This platform ov

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye